Northwest Biotherapeutics EBIT

The latest EBIT for NWBO is $-51M as of June 2026. That compares with $-71M in the prior-year period — up 28.5% year over year. That is below the Healthcare sector average of $2T. Investors often review this figure alongside Northwest Biotherapeutics's historical trend and sector peers before judging valuation or financial health.

Over the past year, NWBO's EBIT moved from $-71M to $-51M — a 28.5% year-over-year increase. If the trend continues in the same direction for several quarters, it can signal a meaningful shift in Northwest Biotherapeutics's operating scale or balance-sheet position.

Against Healthcare companies, NWBO currently prints $-51M for EBIT, while the sector average sits near $2T. That is roughly 100.0% below the sector mean. Large gaps often invite a closer look at Northwest Biotherapeutics's growth, margins, and balance sheet.

A EBIT figure of $-51M for NWBO is a snapshot of scale on that line item. On its own it does not say whether the business is healthy — you also want growth rate, margins, and how the number compares with similar companies. The Healthcare average is about $2T. Explore the charts below for those layers of context.

After noting NWBO's EBIT ($-51M), review year-over-year change from $-71M, peer averages, and a few neighboring metrics such as revenue, margins, or valuation multiples. That combination usually beats staring at a single figure. The navigation links on this page jump you to those related views.